Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

O n any given day, millions of people in the U.S. are trying to lose weight. Recent data from the Centers for Disease Control and Prevention reports that a little over 40% of adul ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...

Just eight seconds into the start of the 2025 award show season, Nikki Glaser, the host of the 82nd Golden Globes, dubbed the ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

GlobaData issued a report stating that it expects Eli Lilly’s Zepbound to lead the obesity market in the ... According to its approval, the medication should be used alongside a reduced calorie diet ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...